

TABLE OF CONTENTS

Book 4

| | |
|---|------|
| Preface | i |
| Editorial Board | ii |
| Book 4 Panel | iii |
| Continuing Education and Program Evaluation Instructions | viii |
| Roles of ACCP and BPS | xi |

Geriatrics I

FALLS PREVENTION

| | |
|---|----|
| Learning Objectives | 1 |
| Introduction | 1 |
| Epidemiology | 1 |
| Etiology | 2 |
| Overview | 2 |
| Drugs | 2 |
| Complications and Prognosis | 9 |
| Therapeutic Goals and Outcomes | 10 |
| Quality Patient Care | 10 |
| Falls Prevention | 10 |
| Assessment | 10 |
| Management | 11 |
| Single Interventions | 11 |
| Multifaceted Interventions | 13 |
| Hip Protectors | 13 |
| Vitamin D and Calcium Supplementation | 13 |
| Osteoporosis Prevention and Treatment | 13 |
| Patient Education | 14 |
| Effectiveness and Future Directions | 14 |
| Conclusion | 14 |
| Annotated Bibliography | 15 |
| Self-Assessment Questions | 17 |

URINARY INCONTINENCE AND BOWEL DISORDERS IN THE ELDERLY

| | |
|--|----|
| Learning Objectives | 21 |
| Introduction | 21 |
| Urinary Incontinence | 21 |
| Introduction | 21 |
| Pathophysiology | 22 |
| Classification | 23 |
| Urge Incontinence | 23 |
| Stress Incontinence | 23 |
| Overflow Incontinence | 24 |
| Mixed Incontinence | 24 |
| Functional Incontinence | 24 |
| Clinical Evaluation | 24 |
| Therapeutic Goals | 26 |
| Non-pharmacological Treatments | 26 |
| Behavioral Modifications | 27 |
| Toilet Assistance | 27 |
| Bladder Training | 28 |
| Pelvic Muscle Rehabilitation | 28 |
| Biofeedback | 29 |
| Pelvic Floor Electrical Stimulation | 29 |
| Pelvic Organ Support Devices | 29 |
| Pharmacological Treatments | 30 |
| Drugs used for Urge Incontinence | 30 |
| Anticholinergics | 30 |
| Tricyclic Antidepressants | 33 |
| Drugs used for Stress or Mixed Incontinence | 33 |
| α -Adrenergic Agonists | 33 |
| Estrogens | 33 |
| Tricyclic Antidepressants | 33 |
| Serotonin Norepinephrine Reuptake Inhibitors | 34 |
| Drugs used for Overflow Incontinence | 34 |
| Surgery | 34 |
| Financial Impact of UI | 35 |
| Education | 35 |
| Functional Bowel Disorders | 35 |
| Constipation | 36 |

| | |
|---|----|
| Causes and Physiological Considerations | 36 |
| Changes Associated with Aging | 37 |
| Medical Complications | 37 |
| Patient Evaluation | 38 |
| Treatment of Constipation | 38 |
| Non-pharmacological Therapies | 38 |
| Pharmacological Therapies | 39 |
| Bulk Laxatives | 39 |
| Osmotic Laxatives | 39 |
| Saline Laxatives | 40 |
| Stimulant Laxatives | 40 |
| Surfactant Laxatives | 40 |
| Other Therapies | 40 |
| Comparative Efficacy | 41 |
| Managing Specific Patient Situations | 41 |
| Patient Education | 42 |
| Fecal Incontinence | 42 |
| Conclusion | 43 |
| Annotated Bibliography | 43 |
| Self-Assessment Questions | 45 |

PREVENTION AND TREATMENT OF PRESSURE

ULCERS

| | |
|--|----|
| Learning Objectives | 49 |
| Introduction | 49 |
| Epidemiology | 50 |
| Historical Perspective | 50 |
| Pathophysiology | 50 |
| Overview of the Wound Healing Process | 50 |
| Definition/Types of Wounds | 50 |
| Etiology of Pressure Ulcers | 51 |
| Stages of Pressure Ulcers | 51 |
| Complications | 51 |
| Prevention | 52 |
| Risk Assessment Tools | 52 |
| Norton Scale | 52 |
| Braden Scale | 52 |
| Other Preventive Measures | 52 |
| Skin Care | 53 |
| Mechanical Loading and Support Surfaces for Pressure Relief | 53 |
| Nutrition to Prevent Pressure Ulcers | 54 |
| Treatment | 54 |
| Assessment of Pressure Ulcers | 54 |
| Wound Management | 55 |
| Treatment Goals | 55 |
| Wound Cleansing | 56 |
| Debridement | 56 |
| Wound Dressings | 57 |
| Gauze | 57 |
| Transparent/Polymer Films | 57 |
| Hydrocolloids | 57 |
| Foams | 58 |
| Hydrogels | 58 |
| Alginates | 58 |
| Collagen | 58 |

| | |
|---------------------------------------|----|
| Composites | 58 |
| Principles of Dressing Selection | 59 |
| Prevention and Treatment of Infection | 59 |
| Adjunctive Therapy | 59 |
| Electrical Stimulation | 59 |
| Growth Factors | 60 |
| Skin Equivalents | 61 |
| Radiant Heat | 61 |
| Negative Pressure | 61 |
| Surgical Options | 61 |
| Quality Improvement | 61 |
| Patient/Caregiver Education | 62 |
| Role of the Pharmacist | 63 |
| Conclusion | 63 |
| Annotated Bibliography | 63 |
| Self-Assessment Questions | 65 |

Geriatrics II

HEALTH AND PUBLIC POLICY AS IT AFFECTS

SENIORS

| | |
|--|----|
| Learning Objectives | 71 |
| Introduction | 71 |
| Current Trends in Population Aging | 71 |
| Mortality and Morbidity Compression | 71 |
| Defining Old Age | 72 |
| Vulnerability of Seniors | 72 |
| Health Care Disparities | 72 |
| Distribution of Wealth and Political Clout | 73 |
| Use of Services | 73 |
| National Challenges in Delivery of Health Care to Seniors | 74 |
| Medicare and Medicaid Programs | 74 |
| Medicare Cost-control Efforts | 74 |
| Challenges for Medicare | 74 |
| Coordination of Care | 74 |
| Access to Prescriptions | 74 |
| Stopgap Measures | 75 |
| Medicare Prescription Coverage Legislation | 76 |
| Drug Discount Card | 76 |
| Basic Structure of the Part D Benefit | 76 |
| Medicare Pharmacist Services Coverage | 77 |
| Food and Drug Administration Issues | 77 |
| Long-term Care Alternatives | 78 |
| Assisted Living | 79 |
| Transitional and Skilled Nursing Care | 79 |
| Nursing Home Care | 79 |
| Payers for LTC | 80 |
| Geriatric Education for the Health Care Workforce | 80 |
| Senior Care Pharmacy | 80 |
| Other Health Care Professions | 80 |
| Interdisciplinary Teams in Geriatrics | 81 |
| Summary | 81 |
| Annotated Bibliography | 82 |
| Self-Assessment Questions | 85 |

CHRONIC DISEASE MANAGEMENT IN THE ELDERLY

| | |
|--|------------|
| Learning Objectives | 91 |
| Introduction | 91 |
| Chronic Disease and Mortality Trends | 91 |
| Prevention | 92 |
| Geriatric Assessment | 92 |
| Overview | 92 |
| Pharmacotherapy Specialists and Geriatric Assessment | 93 |
| Goals and Selection of Pharmacotherapy | 93 |
| Chronic Diseases | 94 |
| Cardiovascular Diseases | 94 |
| Hypertension | 94 |
| Hyperlipidemia | 96 |
| Myocardial Infarction | 97 |
| Heart Failure | 98 |
| Atrial Fibrillation | 99 |
| Stroke | 100 |
| Peripheral Arterial Disease | 101 |
| Musculoskeletal Disorders | 101 |
| Osteoarthritis | 102 |
| Rheumatoid Arthritis | 103 |
| Gastrointestinal Diseases | 103 |
| Gastroesophageal Reflux Disease | 103 |
| Peptic Ulcer Disease | 103 |
| Endocrine Disorders | 105 |
| Diabetes Mellitus | 105 |
| Hypothyroidism | 105 |
| Neuropsychiatric Disorders | 106 |
| Parkinson's Disease | 106 |
| Depression | 106 |
| Chronic Obstructive Pulmonary Disease | 107 |
| Ophthalmological Diseases | 108 |
| Age-related Macular Degeneration | 108 |
| Glaucoma | 108 |
| Cataracts | 108 |
| Summary | 109 |
| Annotated Bibliography | 109 |
| Self-Assessment Questions | 111 |

PHARMACOKINETICS AND PHARMACODYNAMICS IN THE ELDERLY

| | |
|--|-----|
| Learning Objectives | 115 |
| Introduction | 115 |
| Defining "Elderly" | 116 |
| Physiology of Aging That Pertains to Pharmacokinetics and Pharmacodynamics | 116 |
| Interpatient Variability | 116 |
| Age-related | 116 |
| Disease State-related | 118 |
| Pharmacokinetics | 118 |
| Absorption | 118 |
| Distribution | 119 |
| Body Composition | 119 |
| Metabolism | 119 |

| | |
|--|------------|
| First-pass Metabolism and High Extraction Ratio Drugs | 119 |
| Cytochrome P450 Enzymes and the Elderly | 120 |
| Phase II Reactions | 120 |
| Enzyme Induction | 120 |
| Disclaimer | 120 |
| Renal Excretion | 121 |
| Age-related Decline in Renal Function | 121 |
| Estimating Renal Function | 121 |
| Pharmacodynamics | 121 |
| Autonomic Nervous System | 121 |
| Central Nervous System | 122 |
| Important Drug Classes | 122 |
| Anticholinergic Drugs | 122 |
| α -Blockers | 122 |
| β -Blockers and β -Agonists | 122 |
| Angiotensin-converting Enzyme Inhibitors/Angiotensin Receptor Blockers | 123 |
| Central Nervous System Depressants | 123 |
| Opioids | 123 |
| Anticoagulants | 123 |
| Nonsteroidal Anti-Inflammatory Drugs | 123 |
| Important Drug Interactions in Elderly Populations | 123 |
| Drug Development, Evaluation, and Product Labeling | 123 |
| Guidelines for Pharmacokinetic and Pharmacodynamic Evaluations in Elderly Patients | 123 |
| Guidelines for Product Labeling Regarding use in Elderly Patients | 124 |
| Practical Implications | 124 |
| Principles for Drug Use | 124 |
| Patient Education | 125 |
| Select Health Care Providers with Experience and Interest in Geriatrics | 125 |
| Seek Advice Before Initiating Self-treatment | 125 |
| Report any Changes in Condition to Health Care Providers | 125 |
| Annotated Bibliography | 125 |
| Self-Assessment Questions | 127 |

Special Populations

WOMEN'S HEALTH

| | |
|----------------------------|-----|
| Learning Objectives | 133 |
| Contraception | 133 |
| Introduction | 133 |
| Nonhormonal Options | 133 |
| Periodic Abstinence | 133 |
| Barrier Methods | 134 |
| Condoms | 134 |
| Diaphragm and Cervical Cap | 134 |
| Vaginal Sponge | 134 |
| Copper IUD | 135 |
| Spermicides | 135 |
| Hormonal Options | 136 |

| | |
|---|-----|
| Combination Contraceptives | 136 |
| Transdermal | 138 |
| Vaginal | 139 |
| Injectable | 139 |
| Progestin-only Contraceptives | 139 |
| Oral | 139 |
| Injectable | 140 |
| Implantable | 140 |
| Hormonal IUDs | 141 |
| Emergency Contraception | 141 |
| Menstrual-related Disorders | 142 |
| Dysfunctional Uterine Bleeding | 142 |
| Introduction | 142 |
| Pathophysiology | 142 |
| Diagnosis | 142 |
| Treatment | 143 |
| Severe Bleeding | 143 |
| Moderate Bleeding | 145 |
| Mild Bleeding | 145 |
| Premenstrual Syndrome/Premenstrual Dysphoric Disorder | 146 |
| Introduction | 146 |
| Etiology | 146 |
| Characteristics | 146 |
| Management | 146 |
| Supportive Therapy | 146 |
| Aerobic Exercise | 146 |
| Dietary Supplementation | 146 |
| Selective Serotonin Reuptake Inhibitors | 147 |
| Spironolactone | 147 |
| Anxiolytics | 147 |
| Combined Oral Contraceptives | 147 |
| Gonadotropin-releasing Hormone Agonists | 147 |
| Dysmenorrhea | 147 |
| Introduction | 147 |
| Etiology | 147 |
| Characteristics | 148 |
| Treatment | 148 |
| Nonsteroidal Anti-inflammatory Drugs | 148 |
| Oral Contraceptives | 148 |
| Alternative Therapies | 148 |
| Menopausal-related Disorders | 148 |
| Introduction | 148 |
| Vasomotor Symptoms | 148 |
| Introduction | 148 |
| Etiology | 149 |
| Management | 149 |
| Non-pharmacological Therapy | 149 |
| Hormone Therapy | 149 |
| Nonhormonal Therapies | 149 |
| Atrophic Vaginitis/Genitourinary Symptoms | 149 |
| Introduction | 149 |
| Etiology | 150 |
| Management | 150 |
| Hormone Therapy | 150 |
| Moisturizers/Lubricants | 150 |

| | |
|-------------------------------------|-----|
| Other | 150 |
| Mood Disorders | 151 |
| Introduction | 151 |
| Etiology | 151 |
| Management | 152 |
| Hormone Therapy | 152 |
| Other | 152 |
| Hormone Therapy: Risks and Benefits | 152 |
| Introduction | 152 |
| Trials | 152 |
| Impact on Place in Therapy | 155 |
| Conclusion | 155 |
| Annotated Bibliography | 155 |
| Self-Assessment Questions | 157 |

MEN'S HEALTH

| | |
|---|-----|
| Learning Objectives | 163 |
| Introduction | 163 |
| Disorders of the Prostate | 163 |
| Pathophysiology | 163 |
| Screening | 165 |
| Epidemiology | 167 |
| Prognosis | 167 |
| Quality Patient Care | 168 |
| Prevention | 168 |
| Treatment Plan | 168 |
| Pharmacotherapy | 169 |
| Phytotherapeutic Drugs | 169 |
| α_1 -Adrenergic Antagonists | 171 |
| Efficacy | 171 |
| Adverse Effects | 171 |
| Effectiveness | 171 |
| 5- α -Reductase Inhibitors | 172 |
| Efficacy | 172 |
| Adverse Effects | 172 |
| Effectiveness | 172 |
| Combination Therapy | 172 |
| Surgery | 173 |
| Efficiency | 173 |
| Monitoring Response to Treatment | 174 |
| Quality Improvement | 174 |
| The Role of the Pharmacist in Caring for Patients with Prostate Disorders | 174 |
| Androgen Deficiency in the Aging Man | 175 |
| Introduction | 175 |
| Pathophysiology | 175 |
| Etiology | 175 |
| Clinical Characteristics | 176 |
| Diagnosis | 176 |
| Screening Recommendations | 176 |
| Epidemiology | 176 |
| Prognosis | 176 |
| Therapeutic Goals | 177 |
| Quality Patient Care | 177 |
| Prevention | 177 |
| Treatment | 177 |

| | | | |
|--|-----|--|-----|
| Dosage Forms | 177 | Psychiatric and Psychosocial Issues in Palliative | |
| Adverse Effects | 178 | Care | 209 |
| Efficacy | 178 | Depression | 209 |
| The Role of the Pharmacist in Androgen | | Anxiety | 210 |
| Deficiency | 179 | Delirium | 211 |
| Erectile Dysfunction | 180 | Pharmacists' Role in Palliative Care | 211 |
| Introduction | 180 | Ethical and Legal Issues in Palliative Care | 212 |
| Pathophysiology | 180 | Advanced Directives | 212 |
| Etiology | 180 | Do-Not-Resuscitate Orders | 212 |
| Diagnosis | 180 | Withholding and Withdrawing Treatment | 212 |
| Screening | 180 | Euthanasia and PAS | 213 |
| Epidemiology | 180 | Pharmacoeconomics of Palliative Care | 213 |
| Prognosis | 181 | Conclusion | 213 |
| Therapeutic Goals | 181 | Annotated Bibliography | 214 |
| Quality Patient Care | 181 | Self-Assessment Questions | 215 |
| Prevention | 181 | | |
| Pharmacotherapy | 181 | | |
| Non-pharmacological Treatment | 182 | | |
| Guidelines | 182 | | |
| Monitoring Response to Treatment | 184 | | |
| System Support for Drug Use Process | 184 | | |
| Pharmacists' Role in Caring for Patients with ED | 184 | | |
| Conclusion | 185 | | |
| Annotated Bibliography | 185 | | |
| Self-Assessment Questions | 187 | | |
| | | | |
| PALLIATIVE CARE | | CULTURAL COMPETENCY IN PHARMACY | |
| Learning Objectives | 191 | PRACTICE | |
| Introduction | 191 | Learning Objectives | 219 |
| Principles and Components of Palliative Care | 192 | Introduction | 219 |
| Pain and Other Physical Symptoms | 193 | Definitions | 220 |
| Pain | 193 | Defining the Scope of Cultural Competency | 220 |
| Assessment | 194 | Rationale | 221 |
| Treatment | 194 | Respond to Demographic Changes in the | |
| Nonsteroidal Anti-inflammatory Drugs and | | United States | 221 |
| Acetaminophen | 195 | Eliminate Health Care Disparities Based in Diverse | |
| Opioids | 196 | Racial, Ethnic, and Cultural Backgrounds | 221 |
| Adjuvants/Coanalgesics | 198 | Improve Health Outcomes and Quality of | |
| Other Adjuvants | 199 | Services | 222 |
| Fatigue | 199 | Meet Legislative, Regulatory, and Accreditation | |
| Pathophysiology | 199 | Mandates | 222 |
| Assessment | 200 | Be Competitive in the Marketplace | 224 |
| Treatment | 201 | Decrease the Likelihood of Liability and | |
| Anorexia/Cachexia | 202 | Malpractice Claims | 224 |
| Pathophysiology | 202 | Understanding Cultural Competence | 225 |
| Assessment | 203 | Stereotyping Versus Generalizing | 225 |
| Treatment | 203 | Cultural Competency Continuum | 225 |
| Nausea and Vomiting | 205 | Acculturation | 227 |
| Pathophysiology | 205 | Recognizing Barriers to Cross-cultural Care | 227 |
| Assessment | 205 | Health Care System Barriers | 227 |
| Treatment | 205 | Organizational Barriers | 228 |
| Dyspnea | 207 | Structural Barriers | 228 |
| Prevalence | 207 | Economic Barriers | 228 |
| Pathophysiology | 207 | Clinical Barriers | 228 |
| Assessment | 207 | Patient Barriers | 229 |
| Treatment | 208 | Understanding Patient Health Beliefs and | |
| | | Perceptions | 229 |
| | | Illness and Disease | 229 |
| | | Patient Explanatory Models | 229 |
| | | Other Considerations | 230 |
| | | Western Medicine | 231 |
| | | Communicating Across Cultures | 231 |
| | | Cultural Values and Styles of Communication | 231 |
| | | Control and Decision-making | 231 |
| | | Civic Ideals | 231 |
| | | Social Interactions | 231 |

| | |
|---|------------|
| Communication Styles | 232 |
| Values of the Predominant Culture | 232 |
| Exploring the Social Context | 232 |
| Understanding Patients' Environments | 232 |
| Exploring Different Cultures | 233 |
| African-American Cultures | 233 |
| American Indian and Alaska Native Cultures | 234 |
| Asian and Pacific Islander Cultures | 234 |
| Hispanic Cultures | 235 |
| Gay, Lesbian, Bisexual, and Transgender Cultures | 236 |
| Immigrant Cultures | 236 |
| Loss of Hearing or Sight Cultures | 237 |
| Religious Cultures | 237 |
| Western United States Culture | 237 |
| Negotiating a Treatment Plan | 237 |
| Establishing a Framework for Cross-cultural Care | 238 |
| Guidelines and Accrediting Bodies | 238 |
| Economic | 240 |
| Linguistic Competence | 240 |
| Implementing Cultural Competency in the Pharmacy | |
| Setting | 242 |
| Increase Self-Awareness | 242 |
| Learn About the Cultures in the Community | 243 |
| Enhance Communication Skills | 243 |
| Acquire Skills to Develop and Use Community Resources | 243 |
| Exploring the Future of Cultural Competency in Pharmacy Practice | 245 |
| Conclusion | 245 |
| Acknowledgments | 245 |
| Annotated Bibliography | 245 |
| Self-Assessment Questions | 247 |